Literature DB >> 28367107

Microsatellite Instability Pathway and EMAST in Colorectal Cancer.

John M Carethers1.   

Abstract

Microsatellite instability (MSI) refers to the biochemical detection of frameshifted microsatellite sequences from genomic DNA. Genesis of MSI is due to defective DNA mismatch repair (MMR) that fails to correct post DNA replicative slippage mistakes at microsatellites. Most of the estimated 100,000 genomic microsatellites are non-coding; however, ~150-300 microsatellites are coding such that, when frameshifted during the pathogenesis of an MSI tumor, can generate immunogenic neopeptide antigens that limit the growth of tumor and prolong patient survival. In addition to the immune reaction and longer survival, patients with MSI colorectal cancers tend to have poorly differentiated tumors with mucinous features that are located in the right colon. Patients with MSI tumors are more resistant to 5-fluorouracil-based adjuvant chemotherapy but may be responsive to PD-1 immune checkpoint blockade. Specific defects of MMR function not only drive MSI but also elevate microsatellite alterations at selected tetranucleotide repeats that may further modify patient outcome.

Entities:  

Keywords:  Constitutional Mismatch Repair Deficiency syndrome; DNA microsatellites; DNA mismatch repair; DNA repair; EMAST (elevated microsatellelite alterations at selected tetranucleotide repeats); Lynch syndrome; Lynch-like syndrome; MLH1 hypermethylation; MSH3; colorectal cancer; dinucleotide repeats; familial; microsatellite instability; mononucleotide repeats; patient outcome; patient survival; sporadic; tetranucleotide repeats; trinucleotide repeats

Year:  2017        PMID: 28367107      PMCID: PMC5373103          DOI: 10.1007/s11888-017-0352-y

Source DB:  PubMed          Journal:  Curr Colorectal Cancer Rep        ISSN: 1556-3790


  60 in total

1.  Both microsatellite length and sequence context determine frameshift mutation rates in defective DNA mismatch repair.

Authors:  Heekyung Chung; Claudia G Lopez; Joy Holmstrom; Dennis J Young; Jenny F Lai; Deena Ream-Robinson; John M Carethers
Journal:  Hum Mol Genet       Date:  2010-04-23       Impact factor: 6.150

Review 2.  DNA testing and molecular screening for colon cancer.

Authors:  John M Carethers
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-17       Impact factor: 11.382

3.  Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome.

Authors:  Eric R Fearon; John M Carethers
Journal:  Gastroenterology       Date:  2014-11-22       Impact factor: 22.682

Review 4.  Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.

Authors:  John M Carethers; Barbara H Jung
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682

Review 5.  Genomic and epigenetic instability in colorectal cancer pathogenesis.

Authors:  William M Grady; John M Carethers
Journal:  Gastroenterology       Date:  2008-09-04       Impact factor: 22.682

6.  Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.

Authors:  Sigurdis Haraldsdottir; Heather Hampel; Jerneja Tomsic; Wendy L Frankel; Rachel Pearlman; Albert de la Chapelle; Colin C Pritchard
Journal:  Gastroenterology       Date:  2014-09-03       Impact factor: 22.682

7.  Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer.

Authors:  Yasushi Hamaya; Carla Guarinos; Stephanie S Tseng-Rogenski; Moriya Iwaizumi; Ritabrata Das; Rodrigo Jover; Antoni Castells; Xavier Llor; Montserrat Andreu; John M Carethers
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

8.  Influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer.

Authors:  John M Carethers; Bhavya Murali; Bing Yang; Ryan T Doctolero; Akihiro Tajima; Ranor Basa; E Julieta Smith; Monte Lee; Ryan Janke; Tina Ngo; Ruth Tejada; Ming Ji; Matthew Kinseth; Betty L Cabrera; Katsumi Miyai; Temitope O Keku; Christopher F Martin; Joseph A Galanko; Robert S Sandler; Kathleen L McGuire
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

9.  Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status.

Authors:  Satoshi Suzuki; Moriya Iwaizumi; Stephanie Tseng-Rogenski; Yasushi Hamaya; Hiroaki Miyajima; Shigeru Kanaoka; Ken Sugimoto; John M Carethers
Journal:  Cancer Biol Ther       Date:  2016-04-26       Impact factor: 4.742

10.  Oxidative stress induces nuclear-to-cytosol shift of hMSH3, a potential mechanism for EMAST in colorectal cancer cells.

Authors:  Stephanie S Tseng-Rogenski; Heekyung Chung; Maike B Wilk; Shuai Zhang; Moriya Iwaizumi; John M Carethers
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more
  22 in total

Review 1.  The colorectal cancer immune microenvironment and approach to immunotherapies.

Authors:  Minoru Koi; John M Carethers
Journal:  Future Oncol       Date:  2017-08-22       Impact factor: 3.404

2.  Assaying Circulating-Tumor DNA To Predict Recurrence of Localized Colon Cancer.

Authors:  John M Carethers
Journal:  Dig Med Res       Date:  2020-12-30

3.  Prognosticators of Long-Term Outcomes of TNM Stage II Colorectal Cancer: Molecular Patterns or Clinicopathological Features.

Authors:  Tai-Chuan Kuan; Shih-Ching Chang; Jen-Kou Lin; Tzu-Chen Lin; Shung-Haur Yang; Jeng-Kae Jiang; Wei-Shone Chen; Huann-Sheng Wang; Yuan-Tzu Lan; Chun-Chi Lin; Hung-Hsin Lin; Sheng-Chieh Huang
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

4.  Immunological Features with DNA Microsatellite Alterations in Patients with Colorectal Cancer.

Authors:  Maide O Raeker; John M Carethers
Journal:  J Cancer Immunol (Wilmington)       Date:  2020

Review 5.  MSI testing : What's new? What should be considered?

Authors:  Josef Rüschoff; Gustavo Baretton; Hendrik Bläker; Wolfgang Dietmaier; Manfred Dietel; Arndt Hartmann; Lars-Christian Horn; Korinna Jöhrens; Thomas Kirchner; Ruth Knüchel; Doris Mayr; Sabine Merkelbach-Bruse; Hans-Ulrich Schildhaus; Peter Schirmacher; Markus Tiemann; Katharina Tiemann; Wilko Weichert; Reinhard Büttner
Journal:  Pathologe       Date:  2021-09-03       Impact factor: 1.011

6.  Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability.

Authors:  Yurong Song; Shaneen S Baxter; Lisheng Dai; Chelsea Sanders; Sandra Burkett; Ryan N Baugher; Stephanie D Mellott; Todd B Young; Heidi E Lawhorn; Simone Difilippantonio; Baktiar Karim; Yuwaraj Kadariya; Ligia A Pinto; Joseph R Testa; Robert H Shoemaker
Journal:  Cancers (Basel)       Date:  2022-06-24       Impact factor: 6.575

7.  The Human DNA Mismatch Repair Protein MSH3 Contains Nuclear Localization and Export Signals That Enable Nuclear-Cytosolic Shuttling in Response to Inflammation.

Authors:  Stephanie S Tseng-Rogenski; Koji Munakata; Daniel Y Choi; Paul K Martin; Supal Mehta; Minoru Koi; Wei Zheng; Yang Zhang; John M Carethers
Journal:  Mol Cell Biol       Date:  2020-06-15       Impact factor: 4.272

Review 8.  [MSI testing : What is new? What should be considered? German version].

Authors:  Josef Rüschoff; Gustavo Baretton; Hendrik Bläker; Wolfgang Dietmaier; Manfred Dietel; Arndt Hartmann; Lars-Christian Horn; Korinna Jöhrens; Thomas Kirchner; Ruth Knüchel; Doris Mayr; Sabine Merkelbach-Bruse; Hans-Ulrich Schildhaus; Peter Schirmacher; Markus Tiemann; Katharina Tiemann; Wilko Weichert; Reinhard Büttner
Journal:  Pathologe       Date:  2021-05-27       Impact factor: 1.011

9.  Racial and ethnic disparities in colorectal cancer incidence and mortality.

Authors:  John M Carethers
Journal:  Adv Cancer Res       Date:  2021-05-05       Impact factor: 5.767

Review 10.  Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities.

Authors:  Sarah J Tabrizi; Michael D Flower; Christopher A Ross; Edward J Wild
Journal:  Nat Rev Neurol       Date:  2020-08-14       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.